OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate

 OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in
            Men with Metastatic Castrate-Resistant Prostate Cancer

SYNERGY Trial to Continue as Planned Following Completion of Interim Efficacy

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 19, 2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 19, 2013 /PRNewswire/
--OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the
SYNERGY trial is continuing as planned per the recommendation of the
Independent Data Monitoring Committee (IDMC).

The primary registration Phase 3 SYNERGY trial is designed to evaluate a
survival benefit for custirsen in combination with first-line docetaxel
chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC).
Approximately 1,023 men have been enrolled to SYNERGY at 140 sites primarily
in North America and Europe. SYNERGY completed enrollment in 2012 and final
survival results are expected to be announced by mid-2014.

"The recommendation for SYNERGY to continue to final analysis is not
surprising as the criteria to achieve statistical significance on the interim
are considerably more stringent than the criteria required for the final
analysis," stated Scott Cormack, President and CEO of OncoGenex. "We do not
believe these results can be interpreted to predict the final outcome of
SYNERGY and we eagerly anticipate the reporting of final survival results next

OncoGenex and custirsen co-development and commercialization partner, Teva
Pharmaceutical Industries, Ltd., continue to remain blinded to all SYNERGY
data and analyses, including details regarding survival and statistical
evaluations. The IDMC also remains blinded to the details of the interim
efficacy data and analyses.

OncoGenex is a biopharmaceutical company committed to the development and
commercialization of new therapies that address treatment resistance in cancer
patients. OncoGenex has a diverse oncology pipeline, with each product
candidate having a distinct mechanism of action and representing a unique
opportunity for cancer drug development.OncoGenexandTeva Pharmaceutical
Industries Ltd.(NYSE:TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. Apatorsen is
currently being evaluated in seven randomized Phase 2 trials for a variety of
cancers and OGX-225 is currently in pre-clinical development. More information
is available at www.OncoGenex.com and at the company's Twitter account:

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements concerning our anticipated
product development activities, such as expected clinical trial completion and
reporting of results and statements regarding the potential benefits and
potential development of our product candidates. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on management's current
expectations and beliefs and are subject to a number of risks, uncertainties
and assumptions that could cause actual results to differ materially from
those described in the forward-looking statements, including, among others,
the risk that our product candidates will not demonstrate the hypothesized or
expected benefits, the risk of delays in our expected clinical trials, the
risk that new developments in the rapidly evolving cancer therapy landscape
require changes in our clinical trial plans or limit the potential benefits of
our product candidates and the other factors described in our risk factors set
forth in our filings with theSecurities and Exchange Commissionfrom time to
time, including the Company's Quarterly Report on Form 10-Q for the quarter
ended September, 2013. The Company undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be required
by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.

Website: http://www.OncoGenex.com
Contact: Media Contact: Jaime Welch, jwelch@oncogenex.com, 604-630-5403 or
Investor Relations Contact: Susan Specht, sspecht@oncogenex.com, 425-686-1535
Press spacebar to pause and continue. Press esc to stop.